# Adjuvant Zoledronic Acid in High Risk Giant Cell Tumour of Bone (GCT)

> **NCT00889590** · PHASE2 · TERMINATED · sponsor: **Leiden University Medical Center** · enrollment: 15 (actual)

## Conditions studied

- Giant Cell Tumor of Bone
- Osteoclastoma

## Interventions

- **DRUG:** Zoledronic acid

## Key facts

- **NCT ID:** NCT00889590
- **Lead sponsor:** Leiden University Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-12
- **Primary completion:** 2015-05
- **Final completion:** 2015-07
- **Target enrollment:** 15 (ACTUAL)
- **Why stopped:** low recruitment with registration denosumab
- **Last updated:** 2016-01-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00889590

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00889590, "Adjuvant Zoledronic Acid in High Risk Giant Cell Tumour of Bone (GCT)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00889590. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*